Reactions 1680, p151 - 2 Dec 2017 Development of acquired resistance: case report A patient [age and sex not stated] received gefitinib for lung adenocarcinoma and developed acquired resistance to The patient, who had a history of lung adenocarcinoma, was started on gefitinib [route and dosage not stated]. A cell growth inhibition test was performed with gefitinib and afatinib. The lung adenocarcinoma cell line (G719S-GR) was established from the malignant pleural effusion. The test showed human epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) resistance in G719S-GR cells with an LC50 of greater than 100µM for either afatinib or gefitinib [time to reaction onset not stated], and indicated that the tumour developed an acquired resistance from the initial treatment with gefitinib. The test result also showed the G719S-GR cells resistant to EGFR-TKI in vitro. The next generation sequencing (NGS) revealed G719S-GR cells harbor EGFR mutations of E709A and G719S along with the amplification of EGFR, MYC, interleukin 7 receptor (IL7R) and fibroblast growth factor receptor 1 (FGFR1) locus. Additionally, the loss of tuberous sclerosis 1 (TSC1), phosphatase and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 2A (CDKN2A) were observed in G719S-GR cells. The loss PTEN was considered to be the mechanism for the development of acquired resistance to gefitinib. Author comment: "We established a lung adenocarcinoma cell line (G719S-GR) from the malignant pleural effusion of a patient whose tumor developed acquired resistance from initial treatment with gefitinib." Osoegawa A, et al. Acquired resistance to EGFR-TKI in an uncommon G719S EGFR mutation. Cancer Research 77 (Suppl. 13): abstr. 4107, No. 13, Jul 2017. Available from: URL: http://doi.org/10.1158/1538-7445.AM2017-4107 [abstract] - Japan 803284992 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera